Abstract
We review the latest literature on the neuropharmacological treatments for acquired nystagmus.Nystagmus may have a significant [corrected] impact on health, yet there is little scientific evidence on which to make firm recommendations for treatment. Acquired pendular nystagmus may respond to gabapentin or memantine; downbeat and upbeat nystagmus to aminopyridines; and periodic alternating nystagmus to baclofen. To improve treatment we need multi-centre, randomised controlled trials using standardised techniques in reporting objective outcomes, with good follow-up duration and careful reporting of side effects.
| Original language | English |
|---|---|
| Pages (from-to) | 147-153 |
| Number of pages | 8 |
| Journal | Practical Neurology |
| Volume | 12 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jun 2012 |
Keywords
- Amines/therapeutic use
- Aminopyridines/therapeutic use
- Baclofen/therapeutic use
- Cyclohexanecarboxylic Acids/therapeutic use
- Gabapentin
- Humans
- Memantine/therapeutic use
- Nystagmus, Congenital/diagnosis
- Nystagmus, Pathologic/diagnosis
- Randomized Controlled Trials as Topic/methods
- Treatment Outcome
- gamma-Aminobutyric Acid/therapeutic use